Composition of gut microbiota and non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Abstract

SummaryThe present systematic review and meta‐analysis aimed to summarize the associations between gut microbiota composition and non‐alcoholic fatty liver disease. To compare the differences between individuals with or without NAFLD, the standardized mean difference and 95% confidence interval were computed for each α‐diversity index and relative abundance of gut microbes. The β‐diversity indices were summarized in a qualitative manner. A total of 54 studies with 8894 participants were included. Overall, patients with NAFLD had moderate reduction in α‐diversity indices including Shannon (SMD = −0.36, 95% CI = [−0.53, −0.19], p < 0.001) and Chao 1 (SMD = −0.42, 95% CI = [−0.68, −0.17], p = 0.001), but no significant differences were found for Simpson, observed species, phylogenetic diversity, richness, abundance‐based coverage estimator, and evenness (p ranged from 0.081 to 0.953). Over 75% of the included studies reported significant differences in β‐diversity. Although there was substantial interstudy heterogeneity, especially for analyses at the phylum, class, and family levels, the majority of the included studies showed alterations in the depletion of anti‐inflammatory microbes (i.e., Ruminococcaceae and Coprococcus) and the enrichment of proinflammatory microbes (i.e., Fusobacterium and Escherichia) in patients with NAFLD. Perturbations in gut microbiota were associated with NAFLD, commonly reflected by a reduction in beneficial species and an increase in the pathogenic species.

Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD

“…Likewise, Escherichia_Shigella was shown to be significantly related to necro-inflammatory activity and fibrosis in the liver biopsy of morbidly obese patients with MASLD [ 32 ]. A recent meta-analysis also confirmed the enrichment of Fusobacterium and Escherichia involved in progressive liver disease through increased pro-inflammatory states in advanced MASLD [ 33 ].…”